Nonetheless, ambiguity persists regarding the extent to which the functional assessment of HR activity can serve as a predictor for the susceptibility of tumor cells harboring BRCA1 or BRCA2 variants to the effects of PARP inhibitors and DNA-damaging agents. The gene discussed is BRCA2; the disease is neoplasm.